Monoclonal antibodyPhase 3 trialInvestigational
Necitumumab
How it works
Necitumumab is an antibody that targets and blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Pancreatic Cancer— EGFR-expressing
Efficacy
In clinical trials, necitumumab in combination with gemcitabine and cisplatin improved median overall survival to approximately 9.1 months compared to gemcitabine and cisplatin alone in patients with EGFR-expressing pancreatic cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.